REDUCE was a multicenter randomized controlled trial that enrolled 664 subjects with PFO and prior stroke. The study compared PFO closure with the Helex Septal Occluder or Cardioform Septal Occluder (Gore, Phoenix, AZ) vs. antiplatelet therapy with aspirin, clopidogrel, or aspirin + dipyridamole. The trial found that the incidence of ischemic stroke was lower with PFO closure than with antiplatelet therapy at a mean of 3.2 years of follow-up.